TABLE 3.

Comparison of adverse events associated with atezolizumab plus bevacizumab combination therapy between patients without portal hypertension (PH(−)) and with portal hypertension (PH(+)).

Event % (n)	Any grade			Grade 3 or 4
	PH(−) (n = 80)	PH(+) (n = 66)	p Value*	PH(−) (n = 80)	PH(+) (n = 66)	p Value*
Varix rupture	0 (0)	4.5 (3)	0.090	0 (0)	4.5 (3)	0.090
Stomach ulcer	1.3 (1)	6.1 (4)	0.18	1.3 (1)	1.5 (1)	1
Gastric antral vascular ectasia	0 (0)	1.5 (1)	0.45	0 (0)	0 (0)	1
Colonic diverticular bleeding	1.3 (1)	1.5 (1)	1	0 (0)	1.5 (1)	0.45
Gastrointestinal perforation	1.3 (1)	0 (0)	1	1.3 (1)	0 (0)	1
Ascites	11.3 (9)	28.8 (19)	0.011	1.3 (1)	3.0 (2)	0.59
Portal vein thrombus	1.3 (1)	9.1 (6)	0.046	1.3 (1)	3.0 (2)	0.59
Stomatitis	1.3 (1)	3.0 (2)	0.59	0 (0)	1.5 (1)	0.45
Interstitial pneumonia	3.8 (3)	1.5 (1)	0.63	0 (0)	0 (0)	1
Fatigue	77.5 (62)	74.2 (49)	0.70	3.8 (3)	4.5 (3)	1
Decreased appetite	56.3 (45)	59.1 (39)	0.74	0 (0)	4.5 (3)	0.090
Rash	10.0 (8)	6.1 (4)	0.26	2.5 (2)	1.5 (1)	1
Pruritus	56.3 (45)	63.6 (42)	0.40	5.0 (4)	4.5 (3)	1
Hypertension	81.3 (65)	84.8 (56)	0.66	27.5 (22)	19.7 (13)	0.33
Proteinuria	68.8 (55)	56.1 (37)	0.12	17.5 (14)	15.2 (10)	0.82
Acute renal failure	10.0 (8)	13.6 (9)	0.61	1.3 (1)	0 (0)	1
Fever	10.0 (8)	22.7 (15)	0.042	0 (0)	3.0 (2)	0.20
Edema	38.8 (31)	45.5 (30)	0.50	6.3 (5)	1.5 (1)	0.22
Diarrhea	23.8 (19)	22.7 (15)	1	1.3 (1)	1.5 (1)	1
Increased AST or ALT	13.8 (11)	21.2 (14)	0.27	6.3 (5)	4.5 (3)	0.73
Thrombocytopenia	2.5 (2)	10.6 (7)	0.079	1.3 (1)	4.5 (3)	0.33
Thyroid dysfunction	7.5 (6)	9.1 (6)	0.77	0 (0)	0 (0)	1
Adrenal insufficiency	3.8 (3)	3.0 (2)	1	0 (0)	0 (0)	1

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.

^*Fisher's exact test or chi‐squared test.